Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bausch & Lomb's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $6,659 Mil. Bausch & Lomb's Total Assets for the quarter that ended in Mar. 2024 was $13,293 Mil.
Therefore, Bausch & Lomb's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.50.
The historical rank and industry rank for Bausch & Lomb's Equity-to-Asset or its related term are showing as below:
BLCO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5 Med: 0.63 Max: 0.88
Current: 0.5
During the past 6 years, the highest Equity to Asset Ratio of Bausch & Lomb was 0.88. The lowest was 0.50. And the median was 0.63.
BLCO's Equity-to-Asset is ranked worse than 68.2% of 871
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs BLCO: 0.50
Bausch & Lomb Equity-to-Asset Historical Data
The historical data trend for Bausch & Lomb's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's Equity-to-Asset
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Equity-to-Asset falls into.
Bausch & Lomb Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bausch & Lomb's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bausch & Lomb Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb (Bausch & Lomb) Business Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLCO has been successfully added to your 